SD leads to low levels of LRP-1 at the BBB (Cai et al., 2018) and increased expression of receptors of advanced glycation end products (RAGE) in the hippocampus and prefrontal cortex, and these changes significantly correlate with the transport and removal of Aβ42, a core CSF biomarker for AD diagnosis (Zhao et al., 2019). The gene discussed is LRP1; the disease is Alzheimer disease.